Zengin, MehmetZergeroğlu, SemaOkcu, OğuzhanBenek, Suat2022-05-112022-05-1120212211-3428https://doi.org/10.1007/s13402-020-00579-5https://hdl.handle.net/20.500.11776/4831Background: Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated. Methods: Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors. Results: We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS. Conclusions: Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted therapies. © 2021, Springer Nature Switzerland AG.en10.1007/s13402-020-00579-5info:eu-repo/semantics/closedAccessColorectal cancerPD-1PDL-2Prognostic biomarkersStage IIImismatch repair proteinprogrammed death 1 ligand 1programmed death 1 ligand 2adultagedArticlecancer patientcancer recurrencecancer riskcancer stagingcancer survivalclinical assessmentcolorectal cancercontrolled studyfemalefollow uphistopathologyhumanhuman tissueimmune responseinflammationmajor clinical studymalemicrosatellite instabilitymicroscopyoverall survivalprimary tumorpriority journalprotein expressionrecurrence free survivalrelapserisk assessmentrisk factorsurgical margintumor microenvironmentArticle442423432Q1WOS:0006089651000032-s2.0-8510002170433469839Q1